PubMed Health⌕ Search

Biomedical subjects

U Frank

Publications and source records attributed to U Frank.

At least 91 records · Page 5Linked to original sources
PubMed1978

The effect of dextransulfate 500 on the pathogenesis of herpes simplex virus infections in weanling mice.

Intraperitoneal (i.p.) injection of Dextran Sulfate (D.S.) 500 during a limited period of time influences the course of herpes simplex-virus-infections. D.S.500 was found to reduce the resistance of mice for some herpes simplex-virus strains (Len, L3--2s, Haase) if given between 16 hours and 2 hours after i.p. infection. The decrease of resistance could be correlated with an increase of the virus content of liver, spleen, brain and spinal cord. Injection of herpes simplex-virus-specific immune serum counteracted the effect of D.S.500 on the course of infections. Conversely, D.S.500 increased the resistance of mice to another group of herpes simplex-viruses (strains D-316, Thea, DD), if given 3 to 8 hours before infection. These effects are ascribed to a special interaction of D.S.500 with macrophages and probably other virus-susceptible cells of the peritoneal cavity and elsewhere with a resulting counteraction to the virus infection.

Adsorption↗
PubMed1978

Multiplication of herpes simplex virus types 1 and 2 in macrophages of NMRI and C57/BL mice.

The multiplication of 8 strains of herpes simplex virus of type 1 and 2 in normal and stimulated macrophages of NMRI and C57/bl mice was tested. Only 3 strains multiplied in normal NMRI macrophages, whereas all strains multiplied in stimulated cells. No multiplication except of one strain was observed in C57/bl macrophages. The multiplication rates of the virus strains correlated well with the determination of the acid-soluble and acid-insoluble thymidine (dTR) radioactivity and autoradiographic studies of infected (normal and stimulated) NMRI and C57/bl macrophages. The influence of the age of mice used for obtaining the macrophages was also studied. In stimulated macrophages more viral DNA was synthesised than in non-stimulated cells.

Age Factors↗
PubMedDate not supplied

In vitro activity of sulbactam plus ampicillin against hospital isolates of coagulase-negative staphylococci and Acinetobacter species.

The antimicrobial susceptibility of 54 recent clinical isolates of coagulase-negative slime- and non-slime-producing staphylococci and 52 Acinetobacter spp. to sulbactam, ampicillin and the combination of both drugs with a 1:1 ratio was studied by means of an agar dilution test. The coagulase-negative staphylococci showed resistance against sulbactam alone, whereas ampicillin as a single agent was nearly as active as sulbactam plus ampicillin (mode of MIC and MBC 0.03 and 4 mg/l vs. 1 mg/l; geometric mean of MIC and MBC 0.38 and 0.56 vs. 0.26 and 0.38 mg/l, respectively). Among slime-producing or non-slime-producing strains, there was no difference in the susceptibility against ampicillin alone compared to the sulbactam/ampicillin combination, with the exception of the higher MBC (mode: 4 mg/l) for slime-producing strains. Both ampicillin and the sulbactam/ampicillin combination were more active against non-slime-producing than slime-producing strains with modes of MIC and MBC of 0.03 vs. 1 or 4 mg/l. Acinetobacter spp. were susceptible to sulbactam alone (mode of MIC and MBC 1 mg/l; geometric mean of MIC and MBC 1.51 and 2.98, respectively), but resistant to ampicillin. However, the sulbactam/ampicillin combination was highly active against Acinetobacter spp. (mode of MIC and MBC 0.5 and 2 mg/l; geometric mean of MIC and MBC 0.74 and 2.08 mg/l, respectively).

Acinetobacter↗
PubMedDate not supplied

An international study on the occurrence of multiresistant bacteria and aminoglycoside consumption patterns.

The correlation between aminoglycoside consumption patterns and the occurrence of aminoglycoside-resistant bacteria from 12 different countries was analyzed. Regional and national data were collected retrospectively and compared. There was evidence of a wide variation of the national aminoglycoside consumption patterns in the different countries. There was a striking correlation of gentamicin resistance and the total national aminoglycoside and national gentamicin consumption. In addition, there was a clear correlation between bacterial resistance inside and outside the hospital to the total amount of aminoglycoside, particularly gentamicin, consumption in hospitals. In a number of countries, an increase in the frequency of gentamicin-resistant bacterial strains could be noticed. For amikacin, only a correlation of staphylococcal resistance in hospitalized patients to the total amount of national aminoglycoside and amikacin consumption could be found.

Aminoglycosides↗
PubMedDate not supplied

Concentrations of sulbactam/ampicillin in serum and lung tissue.

The penetration of sulbactam plus ampicillin into lung tissue was studied in 15 patients undergoing thoracic surgery for pneumonectomy after the administration of 1 g of sulbactam plus 2 g of ampicillin as a 15 min intravenous short infusion. Ampicillin serum concentrations declined from 40.8 mg/l at 1 h to 18.8 mg/l 2-4 h after administration. Concomitant serum concentrations of sulbactam were 25.5 mg/l and 11.8 mg/l, respectively. In lung tissue, peak ampicillin concentrations of 35.6 mg/kg were reached 1.5 h after administration declining slowly to 26.8 mg/kg after 2-4 h. The respective sulbactam concentrations were 8.6 and 5.5 mg/kg. In our study sufficient sulbactam and ampicillin levels active against important pathogenic organisms causing community- and hospital-acquired respiratory tract infections have been achieved in lung tissue, suggesting that the combination sulbactam/ampicillin is suited for the treatment of most community- and hospital-acquired respiratory tract infections as well as for chemoprophylaxis and treatment of postoperative lung infections after thoracic surgery.

Adult↗
PubMedDate not supplied

Shunt nephritis associated with Propionibacterium acnes.

Membranoproliferative glomerulonephritis was observed in a 22-year-old male patient in whom a ventriculoatrial shunt and a ventricular catheter were implanted after he was diagnosed in September 1989 with a cerebral cyst. Propionibacterium acnes infection of a central nervous system shunt was diagnosed. The ventriculoatrial shunt was removed (the catheter had become embedded in tissue and was left in place) and the patient was treated with cefotaxime (3 x 2 g) for 14 days. Renal function improved, but recovery was not complete.

Adult↗
PubMedDate not supplied

Cost-effectiveness of ceftriaxone 1 g vs second-generation cephalosporins in the treatment of pneumonia in general medical wards in Germany.

The cost-effectiveness of ceftriaxone 1 g in the treatment of pneumonia in general medical wards was compared with that of second-generation cephalosporins. A total of 1,706 patients were treated with either a second-generation cephalosporin (cefotiam, cefuroxime) or ceftriaxone (single daily dose of 1 g), and 604 in each group were included in a matched-pair analysis. Cure or improvement in response to monotherapy was observed in 81.4% of patients on cefuroxime/cefotiam vs 91% of those on ceftriaxone (P < 0.0001). Adverse events occurred with equal frequency in both groups (1.9%). In terms of mean hospital costs for antimicrobial medication, the staff required to administer it as well as laboratory and X-ray examinations, effective treatment with ceftriaxone is DM 193/$ 105 (25%) less expensive than effective treatment with a second-generation cephalosporin (P < 0.001). From the perspective of the health insurance, the costs for a patient treated with ceftriaxone are DM 3,910/$ 2,140 vs DM 4,392/$ 2,400 for a patient treated with a second-generation cephalosporin (March 1998: USD 1 = DM 1.83).

Adolescent↗
PubMedDate not supplied

Cost-effectiveness of ceftazidime or imipenem/cilastatin versus ceftriaxone + aminoglycoside in the treatment of febrile episodes in neutropenic cancer patients in Germany.

A three-pronged cost-effectiveness analysis of the treatment of febrile episodes in neutropenic cancer patients was conducted. It included a review of 37 randomized, controlled studies in the MEDLINE and EMBASE databases (1980-1996). Clinical outcomes as well as costs of treatment with imipenem/cilastatin, ceftazidime and ceftriaxone + aminoglycoside were compared. Primary therapy and modification, respectively, were successful in 62 and 27% of patients treated with imipenem/cilastatin, in 56 and 31% with ceftazidime and in 41 and 13% with ceftriaxone + aminoglycoside. From the perspective of a 1,800-bed teaching hospital, the average overall cost per successfully treated patient was DM 7,475 with imipenem/cilastatin, DM 7,810 with ceftazidime and DM 8,963 with ceftriaxone + netilmicin (DM 1 = USD 0.56; 7/97). The costs for the German national economy were imipenem/cilastatin DM 23,828, ceftazidime DM 24,985 and ceftriaxone + netilmicin DM 29,838.

Ceftazidime↗
PubMedDate not supplied

Antimicrobial expenditures and usage at four university hospitals. Baden-Württemberg Interuniversity Study Group.

BACKGROUND: The increasing use of antimicrobiaL drugs is resulting in enormous hospital expenditures. Careful assessment of inappropriate prescribing and a search for more cost-effective treatment strategies are urgently required. Comparisons between hospitals should help identify areas of inappropriate prescribing as well as effective drug use programs, but such analyses may be severely biased if the impact of different case-mixes is not recognized. PATIENTS AND METHODS: We studied antimicrobial usage and expenditures at four state university hospitals in southwestern Germany and assessed the significance of differences between hospital services after adjustment for patient variables. A prevalence survey was done with review of 2,254 charts of patients admitted to the surgical, medical and pediatric services to obtain information on antimicrobial drug prescription and expenditures in the week preceding the survey. RESULTS: According to pharmacy data for the year 1994, maximal differences between these hospitals in the antibiotic costs per patient-day were 1.9-fold (surgical services), 1.5-fold (medical services), and 1.6-fold (pediatric services). In a multivariate analysis, adjusted antibiotic prescription prevalence rates did not differ for medical and pediatric service patients, but did differ for surgical service patients (p = 0.03). Similarly, adjusted expenditures per patient-week differed significantly between hospitals for surgical service patients (p = 0.001), but only marginally for medical (p = 0.14) and pediatric (p = 0.05) service patients. The adjusted difference in expenditures between surgical departments was as large as 2.8-fold (95% CI 1.8 to 4.3) and was primarily related to preferential use of expensive iv antimicrobial drugs. CONCLUSION: In two hospitals, lowest expenditures in either surgery or medicine were associated with active antimicrobial drug use programs suggesting an impact of these programs on drug use and expenditures limited to these services. The identification of such large patient-mix unrelated differences in antimicrobial usage and expenditures offers opportunities for quality improvements and cost reduction.

Adolescent↗
PubMedDate not supplied

In vitro susceptibility to everninomycin of gram-positive nosocomial pathogens isolated from intensive care units in Germany.

BACKGROUND: Gram-positive bacteria are increasingly found to be causative pathogens in nosocomial infections, and the occurrence of vancomycin resistance in enterococci as well as staphylococci has prompted the investigation of alternative antimicrobial agents active against these strains. Everninomycin, a new oligosaccharide antibiotic, has excellent in vitro activity against gram-positive bacteria, including those resistant to vancomycin. However, avilamycin, a related compound, has been used in Europe as a growth promoter in animal food for years and concern has been raised that cross-resistance in clinical isolates may arise. METHODS: We studied a collection of 268 nosocomial gram-positive isolates from intensive care unit patients with nosocomial pneumonia, urinary tract infection and sepsis, using standard in vitro susceptibility testing. RESULTS: It could be shown that all species tested were exquisitely sensitive to everninomycin (MIC(90) of 0.38 microg/ml for Staphylococcus aureus, 0.5 microg/ml for enterococci and 0.75 microg/ml for coagulase-negative staphylococci). Furthermore, no difference could be observed between methicillin-resistant and methicillin-sensitive S. aureus or between Enterococcus faecium and Enterococcus faecalis. CONCLUSIONS: These results suggest that everninomycin is a promising antibiotic for the treatment of nosocomial infections in intensive care unit patients and that the use of a related substance as an additive in animal food has not yet promoted resistance in clinical isolates.

Aminoglycosides↗